Overcoming heparin limitations in high-risk percutaneous coronary intervention: The alternative strategy - Replacing heparin with bivalirudin

Journal of Invasive Cardiology

Volumn 14, Issue SUPPL. B, 2002, Pages

  Henry, Timothy D ^a  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; DESULFATOHIRUDIN; HEPARIN DERIVATIVE; HIRUDIN; HIRULOG; LEPIRUDIN; THROMBIN INHIBITOR;

ANTICOAGULANT THERAPY; BLEEDING; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; HEART INFARCTION; HEPARINIZATION; HUMAN; REVIEW; THROMBOSIS PREVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; CORONARY ARTERIOSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDIN THERAPY; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; RISK FACTORS; SMOKING; TREATMENT OUTCOME; UNITED STATES;

EID: 0036227199     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial
2. Elective coronary angioplasty: Techniques and complications
3. Abrupt vessel closure
4. Defining the optimal activated clotting time during percutaneous coronary intervention: Aggregate results from 6 randomized, controlled trials
5. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study
6. A clinical trial comparing three antithrombotic drug regimens after coronary stenting
7. Even mild renal insufficiency is associated with increased mortality after percutaneous coronary intervention
8. Nonoperative dilatation of coronary-artery stenosis: Percutaneous transluminal coronary angioplasty
9. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty
10. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty
11. Relation between activated clotting time during angioplasty and abrupt closure
12. Post-procedure heparin: Boon or burden?
13. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization
14. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
15. Co-investigators of the National Heart, Lung and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry: Comparison of complications during percutaneous transluminal coronary angioplasty from 1977-1981 and from 1985-1986: The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry
16. Early and long term results of percutaneous transluminal coronary angioplasty in patients 70 years of age and older with angina pectoris
17. Percutaneous transluminal coronary angioplasty in octogenarians
18. Immediate and long term results of percutaneous transluminal coronary angioplasty in patients aged 70 and over
19. Percutaneous transluminal coronary angioplasty in the elderly: Early and long term results
20. Long term results after successful percutaneous transluminal coronary angioplasty in patients over 75 years of age
21. Percutaneous transluminal coronary angioplasty in patients 70 years of age or older: 12 Years' experience
22. Percutaneous transluminal coronary angioplasty in octogenarians
23. Acute coronary events associated with percutaneous transluminal coronary angioplasty
24. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty
25. Comparative safety and efficacy of percutaneous transluminal coronary angioplasty in men and women
26. Results of percutaneous transluminal coronary angioplasty in women: 1985-1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry
27. Percutaneous transluminal coronary angioplasty in women compared with men
28. Low-normal or excessive body mass index: Newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention
29. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention
30. Hemorrhagic complications in association with percutaneous coronary intervention: Can the risk be attenuated?
31. Coronary angioscopy
32. Prevalence of coronary heart disease, left ventricular failure, and hypertension in middle-aged, newly diagnosed type 2 (non-insulin dependent) diabetic subjects
33. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
34. Randomized, placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
35. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
36. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
37. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomized, placebo-controlled trial
38. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
39. Comparison of two glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous revascularization
40. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: The first reanalysis of the bivalirudin angioplasty study
41. Restenosis: The clinical issues
42. Unstable angina: A comparison of angioscopic findings between diabetic and nondiabetic patients
43. Impact of renal disease and treatment type on mortality in patients with clinically significant coronary artery disease
44. Long-term outcome of dialysis patients in the United States with coronary revascularization procedures
45. Prognostic importance of abnormal renal function in patients with acute coronary syndromes
46. The use of bivalirudin in patients with renal impairment
47. Renal failure predisposes patients to adverse outcomes after coronary artery bypass surgery. VA Cooperative Study #5
48. Rate of restenosis after PTCA in patients with terminal renal failure. A quantitative coronary angioplasty study
49. Are patients with renal failure good candidates for percutaneous coronary revascularization?
50. Clinical outcomes of PTCA in chronic renal failure: A case-control study for comorbid features and evaluation of dialysis dependence
51. Bleeding in renal failure
52. Bleeding and thrombosis in chronic uremia
53. Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: Relationship with dyslipidemia, inflammation, and factor VII genotype
54. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment
55. Monocyte expression of tissue factor and adhesion molecules: The link with accelerated coronary artery disease in patients with chronic renal failure
56. Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis
57. Metalloproteinase-9 mmRNA expression in monocytes from patients with chronic renal failure
58. Unstable angina. A classification
59. Risk stratification in unstable angina: Prospective validation of the Braunwald Classification
60. Incidence and follow-up of Braunwald subgroups in unstable angina pectoris
61. Percutaneous coronary intervention for unstable angina
62. Percutaneous angioscopy during coronary angioplasty using a steerable microangioscope
63. Coronary thrombi increase PTCA risk: Angioscopy as a clinical tool
64. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: Results of the Heparin in Early Patency (HEAP) pilot study
65. Three days of heparin pretreatment reduces major complications of coronary angioplasty in patients with unstable angina
66. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris
67. Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty
68. Heparin requirements in coronary angioplasty
69. Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention
70. Low-dose heparin for routine coronary angioplasty and stenting
71. A randomized trial of a fixed high dose versus a weight-adjusted low dose of intravenous heparin during coronary angioplasty
72. Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and hirudin
73. Putting heparin into perspective: Its history and the evolution of its use during percutaneous coronary intervention
74. Role of thrombin signalling in platelets in hemostasis and thrombosis
75. Thrombin signalling and protease-activated receptors
76. Heparin binding and neutralizing proteins
77. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin
78. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety
79. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low molecular weight heparin and with a direct thrombin inhibitor
80. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin and hirudin of coagulation activation during rtPA-induced thrombolysis
81. Protection of factor Xa from neutralization by the heparin-antithrombin complex
82. Inhibition of factor IXa and factor Xa by antithrombin III/heparin during factor X activation
83. Selective immobilization of alpha-thrombin by surface-bound fibrin
84. Human alpha-thrombin binding to nonpolymerized fibrin-sepharose: Evidence for an anionic binding region
85. Inhibited thrombins. Interactions with fibrinogen and fibrin
86. Modulation of thrombin and heparin activities by fibrin
87. Formation of a ternary complex between thrombin, fibrin monomer, and heparin influences the action of thrombin on its substrates
88. Binding of fibrin monomer and heparin to thrombin in a ternary complex alters the environment of the thrombin catalytic site, reduces affinity for hirudin, and inhibits cleavage of fibrinogen
89. Low-molecular-weight heparin
90. The thrombin-specific anticoagulant, bivalirudin, completely inhibits thrombin-mediated platelet aggregation
91. Clot-bound thromin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
92. Beyond heparin and aspirin: New treatment for unstable angina and non-Q-wave myocardial infarction
93. Direct thrombin inhibitors in acute coronary syndromes: Principle results of a meta-analysis based on individual patient data
94. Novastan (brand of argatroban): A small-molecule direct thrombin inhibitor
95. A randomized, blinded study of two doses of Novastan® (brand of argatroban) versus heparin as adjunctive therapy to recombinant tissue plasminogen activator (accelerated administration) in acute myocardial infarction: Rationale and design of the Myocardial Infarction using Novastan® and t-PA (MINT) study
96. Leeches to hirulogs and other thrombin-directed antithrombotics
97. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study
98. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: A randomized trial
99. Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: Final results of a pilot study. HIT-1 (Hirudin for the Improvement of Thrombolysis)
100. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia
101. Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention
102. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty
103. Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention
104. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
105. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty
106. Antithrombin, antiplatelet therapy or both during PCI: A preliminary randomized trial
107. Pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade: Results of the REPLACE-1 trial
108. Clinical outcomes of bivalirudin for ischemic heart disease
109. Complex and multivessel treatment